Nuveen LLC Makes New $10.68 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Nuveen LLC has made a new investment in BioCryst Pharmaceuticals, acquiring 1,423,646 shares valued at approximately $10.68 million, representing about 0.68% of the company.
• BioCryst Pharmaceuticals recently reported a 49.5% increase in revenue year-over-year, with earnings per share of $0.15, significantly exceeding estimates of $0.03.
• Analysts are optimistic about BioCryst, with nine analysts rating it as a "Buy" and one as a "Hold," and a consensus target price of $16.70.

Nuveen LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,423,646 shares of the biotechnology company's stock, valued at approximately $10,677,000. Nuveen LLC owned 0.68% of BioCryst Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of BCRX. Jupiter Asset Management Ltd. increased its position in BioCryst Pharmaceuticals by 82.4% in the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after buying an additional 971,040 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $3,983,000. Woodline Partners LP purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $3,385,000. Caligan Partners LP raised its position in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after buying an additional 412,347 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 64.5% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,042,424 shares of the biotechnology company's stock valued at $7,818,000 after purchasing an additional 408,560 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.10% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock traded down $0.17 on Monday, hitting $8.39. 2,502,948 shares of the company's stock were exchanged, compared to its average volume of 3,348,017. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.01 and a 12-month high of $11.31. The firm has a 50 day moving average price of $8.79 and a two-hundred day moving average price of $8.79. The stock has a market cap of $1.76 billion, a P/E ratio of -46.61, a price-to-earnings-growth ratio of 1.94 and a beta of 1.10.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. During the same quarter last year, the firm earned ($0.06) earnings per share. The firm's quarterly revenue was up 49.5% compared to the same quarter last year. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on BCRX. JPMorgan Chase & Co. raised their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Bank of America raised their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Wedbush raised their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday, June 30th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target on the stock. Finally, Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.